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Background: Suboptimal adherence to medication increases mortality and morbidity; individually tailored 
supportive interventions can improve patients’ adherence to their medication regimens.  
Aims: The study aims to use a pilot randomised controlled trial (RCT) to test the hypothesis that a theory-
based, nurse-led, multi-faceted intervention comprising motivational interviewing techniques and text 
message reminders in addition to standard care will better promote medication adherence in cardiac patients 
compared to standard care alone. The pilot study will assess self-reported adherence or non-adherence to 
cardiovascular medication in patients referred to a cardiac rehabilitation program following hospital 
admission for an acute cardiac event and test the feasibility of the intervention. The study will examine the 
role of individual, behavioural and environmental factors in predicting medication non-adherence in patients 
with CVD. 
Methods: This is a mixed-methods study including a nested pilot RCT. Twenty-eight cardiac patients will 
be recruited; an estimated sample of nine patients in each group will be required for the pilot RCT with 80% 
power to detect a moderate effect size at 5% significance, and assuming 50% loss to follow-up over the six 
month intervention. Participants will complete a paper-based survey (Phase one), followed by a brief semi-
structured interview (Phase two) to identify their level of adherence to medication and determine factors 
predictive of non-adherence. Participants identified as ‘non-adherent’ will be eligible for the pilot 
randomised trial, where they will be randomly allocated to receive either the motivational interview plus 
text message reminders and standard care, or standard care alone. 
Discussion: Nurse-led multi-faceted interventions have the potential to enhance adherence to cardiac 
medications. The results of this study may have relevance for cardiac patients in other settings, and for long-
term medication users with other chronic diseases. 
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Summary of Relevance 
Problem 
Cardiovascular disease remains one of the leading causes of morbidity and mortality in Australia and 
worldwide. 
What is already known 
Adherence to cardiovascular medication is suboptimal, increasing the risk of mortality and morbidity. 
What this paper adds  
This is the first multi-method pilot randomised controlled trial of an intervention comprising 
motivational interviewing techniques and text reminders delivered by nurses to promote adherence to 
medication. Outcomes will support the development of a full-scale trial of the intervention in cardiac 
rehabilitation and other health care areas, and to patients with other chronic conditions who take long-















World-wide, the prevalence of cardiovascular disease (CVD) is increasing rapidly because of changes 
in population lifestyles (Hauptman, 2008), resulting in major concerns for community health (Zhu, 
Wang, Zhu, Zhou, & Wang, 2015). Cardiovascular disease has emerged as a leading cause of death and 
disability in Australia (Nichols, Peterson, Alston, & Allender, 2014), affecting one in six people and 
responsible for 16% of the nations’ total disease burden. It is the main reason for rehospitalisation 
(Australian Institute of Health and Welfare, 2014); costs in 2004-5 of AU$5.94 billion accounted for 
11% of Australia’s total health expenditure (Australian Institute of Health and Welfare, 2010). Quality 
of life has been shown to improve for patients with CVD referred to a comprehensive cardiac 
rehabilitation and secondary prevention program (Shepherd & While, 2012). These programs comprise 
recovery and preventative activities aimed at modifying cardiac risk factors and enhancing physico-
psycho-social function to reduce the risk of subsequent cardiac events (Woodruffe et al., 2014). Cardiac 
rehabilitation enables changes in patient lifestyles by providing education and development of skills to 
reduce cardiovascular risk factors, and to promote adherence to prescribed medications.  
Prescription medications, an important form of secondary prevention for CVD, have been a key 
factor in the 20% reduction seen in mortality rates within one year of diagnosis of acute myocardial 
infarction (AMI) (Chase, Bogener, Ruppar, & Conn, 2016); and the 28% reduction within three months 
of AMI between 2006 and 2007 (Kolandaivelu, Leiden, Gara, & Bhatt, 2014). While cardiac 
medications have been shown to be effective for symptom management and slowing the progression of 
CVD, consistent adherence to prescribed medication regimes is required to achieve these effects (Hunt 
et al., 2009).  
The World Health Organisation (WHO) defines adherence as ‘the extent to which a person’s 
behaviour (taking medications, following a recommended diet and/or executing lifestyle changes) 
corresponds with the agreed recommendations of a healthcare provider’ (Sabaté, 2003, p. 3). Adherence 
to medications is a challenge, particularly for patients with cardiac disease who often require  multiple 
medications for prolonged periods (World Health Organisation, 2003). The risk of mortality and 





Tu, Young, & Murray, 2004); yet reported rates of non-adherence vary from 33% to more than 50% 
(Li, Kuo, Hwang, & Hsu, 2012; Munger, Van Tassell, & LaFleur, 2007; Shah, Desai, Gajjar, & Shah, 
2013), contributing to increased numbers of CVD-related Emergency Department visits, 
hospitalisation, reduced health and well-being, augmented healthcare costs and risk of death (Mukhtar, 
Weinman, & Jackson, 2014; Whittle et al., 2016). It is therefore important to identify the factors that 
influence medication adherence (Munger et al., 2007) and provide tailored interventions to improve 
patients’ medication-taking behaviours (Santo et al., 2016). 
Background 
Medication adherence is linked to better clinical outcomes among patients with heart disease, reducing 
the risk of hospital readmission and death (Ruppar, Cooper, Mehr, Delgado, & Dunbar Jacob, 2016). 
Suboptimal medication adherence is a multidimensional issue. Socio-economic and patient-related 
factors include low educational levels, inadequate knowledge about disease and medications, beliefs 
about medications and patients’ motivation to manage their illness and improve their overall health 
(Broekmans, Dobbels, Milisen, Morlion, & Vanderschueren, 2010). Lack of social support and 
psychological, cognitive or medical vulnerability can also play a part (Kronish & Ye, 2013). Factors 
shown to predict medication non-adherence include low self-efficacy, attitudes and beliefs about 
medications, low perceived behavioural control, and lack of social support (Morrison et al., 2015). 
Patients with concerns about their medications are more likely to report forgetting to take them or 
intentionally skipping doses (World Health Organisation, 2003). Older people and people in poor health 
or with co-morbidities are less likely to successfully self-administer (Krueger et al., 2015). Medication 
self-efficacy and beliefs about medications may also influence the adoption and maintenance of 
medication adherence behaviours (Bane, Hughe, & McElnay, 2006), and these factors can be affected 
by psycho-social factors such as the perceived level of social support and mood (Cha, Erlen, Kim, 
Sereika, & Caruthers, 2008).  
Exploring patients’ emotions and beliefs while helping to strengthen their self-efficacy may 
minimise barriers to behavioural change and motivate them to adhere to their medications (Riegel, 





exploring what drives an individual patient to make changes or to maintain the status quo. This can be 
achieved by applying motivational interviewing techniques that have been found to be effective in 
assessing a patient’s readiness to change and subsequently moving toward change at an appropriate 
time (Dart, 2010). Motivational interviewing has been shown to be effective in increasing medication 
adherence in cardiac patients (Ogedegbe et al., 2008). Also, text messages have been effective in 
improving the use of prescribed cardiac medications among 65% of patients at six months (Wald, 
Bestwick, Raiman, Brendell, & Wald, 2014). Understanding the reasons for poor adherence may 
suggest approaches to novel interventions. 
Theoretical framework guiding the study 
This study will use Bandura’s social cognitive theory to enhance the refinement of self-efficacy 
(Bandura, 1977) and to examine the effects of individual, behavioural and environmental factors on 
medication adherence. According to the theory, self-efficacy is the pivotal determinant in influencing a 
person’s particular behaviour, directly affecting one’s actions and impacting on other determinants 
(Bandura, 1977, 2004). Bandura (2004) notes that self-efficacy determines the expected outcomes of 
people’s behaviours. Reciprocal determinism is the basic organising principle of behaviour change 
proposed by this social cognitive theory, with continuous, functional interaction between the 
environment, the individual and behaviour (Bandura, 1998) (Figure 1). It assumes that a change in 
knowledge of health risk and benefits is essential, but requires additional impacts for change to occur 
(Munro, Lewin, Swart, & Volmink, 2007). Other determinants of behaviour change include behaviours, 
outcome expectations, expected benefits, beliefs and goals, and perceived facilitators and barriers. The 
theory proposes that if people perceive that they have outcome control, appropriate behaviour will 
follow, with sufficiently high self-confidence to overcome otherwise insurmountable barriers (Armitage 
& Conner, 2000).  
Using a theoretical basis to explain relationships between study variables is important when 
designing effective behavioural change studies (Short, James, & Plotnikoff, 2013). Appropriately 
designed interventions that employ multiple strategies, such as motivational interviewing to encourage 





significant increases in medication adherence in cardiac patients (Al Ganmi, Perry, Gholizadeh, & 
Alotaibi, 2016). 
Methods 
Aim and hypothesis 
The study aims to use a pilot randomised controlled trial (RCT) to test the hypothesis that a theory 
based, nurse-led, multi-faceted intervention comprising motivational interviewing techniques and text 
message reminders in addition to standard care will better promote medication adherence in cardiac 
patients compared to standard care alone. Underpinning evidence and assumptions of the hypothesis 
are that: 
1) A high proportion of patients fail to adhere to their cardiovascular medication regimens. 
2) Medication adherence self-efficacy, patient beliefs, and lack of social support are predictive factors 
associated with non- adherence to medication. 
3) High quality evidence supports the use of multi-faceted interventions comprising of motivational 
interviewing counselling combined with text messaging reminders to promote medication adherence. 
The pilot study will assess self-reported adherence or non-adherence to cardiovascular medication in 
patients referred to a cardiac rehabilitation program following hospital admission for an acute cardiac 
event and test the feasibility of the intervention. Medication non-adherence has been defined as ‘taking 
less than 80% of prescribed doses and can also include taking too many doses’ and it is associated with 
an increased risk of poor health, adverse clinical events and death (Nieuwlaat et al., 2014). The study 
will examine the role of individual, behavioural and environmental factors in predicting medication 
non-adherence in patients with CVD. 
Study design  
This is a mixed methods study which includes a nested, pilot RCT. Both qualitative and quantitative 
methods are required to address the study’s aims and hypothesis. The use of mixed methods is valuable 
to provide a fuller picture of the topic and to transcend the limitations of each of the methods used 





In this study, data collection will occur sequentially: quantitative data collection followed by 
qualitative data collection will occur for the exploratory phases that will provide the explanatory power 
in support of the final (RCT) intervention testing phase: (QUAN + qual) → QUAN. Results from the 
exploratory phases (survey design and semi-structured interviews) will inform the fine tuning of the 
intervention in the third phase.  
This multi-method study will entail three interrelated phases:  
Phase one: The survey is designed to identify cardiac patients’ patterns of medication 
adherence and their associated degree of adherence. The purpose of the survey is to gather quantitative 
data about medication adherence, patient behaviours, beliefs and other associated factors, including 
demographic data which will inform intervention and form baseline data.  
Phase two: A descriptive qualitative study will explore the phenomena of cardiac patients’ 
adherence to medications and how they respond to factors that affect medication adherence. Using semi-
structured interviews, patients’ views of their cardiac medications will be explored as well as the factors 
that influence their medication adherence.  
 A semi-structured interview format was chosen because of its flexibility in collecting self-reporting 
data (Cohen & Crabtree, 2006), enabling participants to talk freely about issues related to their 
medication adherence and telling stories in their own words. Semi-structured in-depth interviews will 
involve open-ended questions to elicit detailed narratives and stories (Whiting, 2008). This will provide 
in-depth understanding to supplement and explain quantitative results from Phase one.  
Details of Phase one and Phase two data will be used to inform motivational interviewing 
techniques and to tailor the interventions to individual patients’ needs to better support their adherence 
to cardiac medications. 
Phase three, a pilot RCT: Participants identified as non-adherent to their medications in Phase 
one (based on Medication Adherence Questionnaire [MAQ] scores) and Phase two data (themes and 
patterns of medication adherence/non-adherence) will be invited to take part in this pilot trial. This will 
pilot test the feasibility and effectiveness of a multi-faceted intervention strategy, including 
motivational interviews plus text message reminders, to influence adherence to their cardiac medication 





by a cardiac rehabilitation program and the same program augmented by this multi-faceted intervention. 
The feasibility of conducting a multi-faceted behavioural intervention in a busy cardiac rehabilitation 
setting will be investigated. We also sought data to determine the effect size for sample-size calculation 
as we could only extrapolate an estimated effect size from a somewhat similar trial for the sample size 
calculation of this pilot study. Data are currently lacking for full-scale trial of this approach among 
cardiac rehabilitation patients.  
Study setting and participants 
The study will be carried out in the cardiac rehabilitation centre of a tertiary referral hospital in Sydney, 
Australia. Participants will be cardiac patients referred to a cardiac rehabilitation program following 
their admission for an acute cardiac event; those participating in the pilot trial will be randomly allocated 
to receive either the intervention plus standard care or standard care only. Inclusion criteria are: 18 years 
of age or older; diagnosed with cardiac disease and referred to the hospital cardiac rehabilitation 
program; currently taking at least one cardio-protective medication, and having primary responsibility 
for taking their own medications (i.e. not reliant on a carer). Participants must be able to read, speak 
and understand English, have a personal mobile phone, and be able to receive and reply to phone calls 
and text messages. Patients who are blind, deaf or unable to consent to receiving text messages will be 
excluded. Those clinically judged to have cognitive impairment that limits their ability to understand 
and answer the study questions will also be excluded.  
Sample size determination 
The sample size for the pilot RCT was based on data from Ma, Zhou, Zhou, and Huang (2014). Using 
a two-sided test, moderate effect size with α = 0.05, and power = 0.80, nine participants are required in 
each group. Allowing for 50% loss, a total of 28 cardiac patients will be needed for the pilot RCT.  
Around 350 patients per year (30 per month) are estimated to attend the cardiac rehabilitation centre. 
Pilot data indicate around one third are considered non-adherent to medications. If 50% of eligible 
patients agree to participate, recruitment will progress at five participants per month (a rate of 





the study will take approximately six months for recruitment and six more months for intervention and 
follow-up.  
Study procedures and data collection 
Data collection will take place at baseline and at six months, and changes in medication adherence will 
be compared within and between groups to determine any intervention effect. The Consolidated 
Standard of Reporting Trials (CONSORT) diagram of study processes is presented in Figure 2. Baseline 
survey and interview data will be collected during patients’ hospital attendance for a cardiac 
rehabilitation session. Pilot RCT participants will repeat the Phase one survey via telephone interview 
at six months post-randomisation to collect the follow-up data; three additional open-ended questions 
(see Appendix 1) will explore participants’ experiences of the motivational interview and the text 
messaging, and enquire whether anything else might have helped adherence.  
In Phase two each interview will involve a face-to-face meeting for an interview guided by a 
set of questions or topics (Polit & Beck, 2004). Interviews will be arranged with participants using 
preferred communication methods with reminders two days beforehand. The guide for the individual 
semi-structured interviews can be found in Appendix 2. Data collection, transcription and analysis will 
be conducted, with questions modified in light of responses and emergent themes (Braun & Clarke, 
2006).  
Recruitment, enrolment and consent 
Recruitment will occur under the supervision of the clinical nurse consultant for cardiac rehabilitation, 
with the agreement of the director of nursing and the cardiology consultant. Patients referred to the 
cardiac rehabilitation program will be screened using the study inclusion/ exclusion criteria by the 
clinical nurse consultant at their first session. Eligible members of a consecutive cohort of patients who 
express interest in the project will be referred to the researcher, who will explain the study phases and 
provide an information statement and consent form. Completion of the survey will identify patients who 
are non-adherent with at least one cardiac medication, based on their answers to the MAQ with their 





the semi-structured interview (Phase two), eligible participants will be informed about Phase three, the 
pilot RCT, and invited to participate. 
The researcher will obtain written informed consent from participants for Phases one and two; 
similar consent to participate in the pilot trial will be obtained separately. Participants will receive a 
folder at enrolment, including written information about the study and a copy of their consent form, to 
supplement the face-to-face explanation of the study. 
Randomisation and blinding processes  
In the pilot RCT, participants will be randomly assigned to either intervention or control group after 
they have consented to the trial phase. A computerised random number generator will be used to 
generate the random sequence. Using permutated blocks equal numbers of participants will be assigned 
to each group. Sequentially numbered sealed envelopes will be used to conceal the sequence until 
participants are assigned. Neither the participants nor the researcher can be blinded to the group 
allocation because of the nature of the behavioural intervention. A behavioural intervention such as 
motivational interviewing is not easily delivered blinded, and it is unlikely that cardiac patients in a 
cardiac rehabilitation program would not know which intervention they are receiving (Page & Persch, 
2013). Outcome data are self-reported, but the assessor who will collect the outcome data will be 
blinded to study allocation to reduce potential bias. 
The study intervention 
Approaches such as motivational interviewing aim to encourage behaviour change through influencing 
individual’s feelings, thoughts, and confidence to change their behaviours, for example: adhere to a 
recommended medical regimen. The technique facilitates behaviour change by resolving patients’ 
ambivalence to change (Miller & Rollnick, 2002). Motivational interviewing has been incorporated into 
several successful medication adherence interventions (Solomon et al., 2009). Using this technique, a 
wide variety of medication non-adherence factors are targeted, enabling patients to reflect on perceived 
barriers and search for solutions (Easthall, Song, & Bhattacharya, 2013). The interviewing ‘elicits a 
range of possible actions and affirms the patient’s autonomy to make informed choices’ (Riegel et al., 





be mediated by patients’ beliefs about their ability to cope, to locate optimistic changes in their social 
relations and to improve their individual confidence (Luszczynska, Sarkar, & Knoll, 2007). Social 
cognitive theory has previously been applied to examine medication adherence among CVD patients 
(Haskell et al., 1994), to foster individuals’ medication adherence by setting goals and creating firm 
commitments to them, thereby encouraging patients to exercise more control over behaviours. In turn 
patients can come to believe they have a higher ability to adhere to their medications (Smith, Rublein, 
Marcus, Brock, & Chesney, 2003). 
Text messaging has been widely used to improve health behaviours across multiple diseases 
(Spoelstra et al., 2015). It has been used to improve medication adherence by affecting different 
elements of cognition and evoking attention and an automatic response (Yiend, 2010). Text Messaging 
is widely available low-cost, patient friendly, requires low technological expertise and is applicable in 
a diverse range of health behaviours, acting as a safety-net for medication reminders (Cole-Lewis & 
Kershaw, 2010; Zallman, Bearse, West, Bor, & McCormick, 2016).  
Intervention arm 
Participants in the intervention group will receive current standard care through the cardiac 
rehabilitation program plus behavioural counselling about medication adherence using motivational 
interviewing and text reminders. The current cardiac rehabilitation program includes a single one-hour 
information session on cardiac medication. The content received by both group participants will be 
recorded and compared to check for equivalence between the groups. 
Each patient in the intervention group will receive approximately 30 to 40 minutes of a single 
motivational interview-style counselling session (Ma et al., 2014). The essence of motivational 
interviewing is for the counsellor to be simultaneously sympathetic and supportive, as well as directive 
in moving patients toward behaviour change by strengthening their reasons to change (Levensky, 
Forcehimes, O'Donohue, & Beitz, 2007). As part of the counselling, the researcher will provide 
information that the patient may need, and explore barriers that keep the patient from adhering to the 
medication regimen (Dart, 2010). A structured counselling script will be designed that can be tailored 





the session are available in Appendix 3. The sessions will be audiotaped and reviewed by a clinician 
qualified in motivational interviewing to ensure fidelity (Ma et al., 2014).  
Text message reminders will be sent daily for the first two weeks, then on alternate days for 
fortnight, then once a week for the next five months, for a total of six months (Wald et al., 2014). The 
content will vary according to each patient’s non-adherence factors. Examples are supplied in Table 1.  
Control arm 
For the period of the study, patients in the control arm will be provided only with current standard care, 
which includes the provision of cardiac care knowledge and recommendations to enhance medication 
adherence and to promote healthy lifestyles; they will complete the same surveys as the intervention 
arm at baseline and at six months. 
Outcomes 
The primary outcome is medication adherence/ non-adherence at six months. Medication adherence 
will be determined based on participants’ responses to the MAQ (Morisky, Green, & Levine, 1986). 
Patients with a sum score of 1-2 will be considered ‘adherent’; those with a score of 3 - 4 as ‘non-
adherent’ (Morisky et al., 1986).  
Secondary outcomes include identification of those factors exerting a significant influence on 
medication adherence, such as behaviour (self-regulation), beliefs (general harm; general overuse; 
specific necessity; and specific concerns), social support and self-efficacy using a combination of 
instruments, outlined below.  
To assess the acceptability of the intervention at six months, the researcher will telephone each 
member of the intervention group to evaluate their experience of the interview and text messages (see 
Appendix 1).   
Study instruments 
The survey will include a set of questionnaires designed to gather data about medication adherence and 
patient behaviours, beliefs and other factors associated with adherence/ non-adherence. The survey will 





Sociodemographic and health data will be collected: age, gender, living arrangement, level of education, 
ethnicity; co-morbidities. 
The use of different instruments in this study will enable comprehensive study of factors 
contributing to medication non-adherence in patients with CVD, including behavioural and 
psychological factors. Motivational interviews in the RCT phase will focus on the identified non-
adherence factors for each individual patient. 
Medication non-adherence will be assessed by the Medication Adherence Questionnaire 
(MAQ) (Morisky et al., 1986), which is designed to measure medication adherence behaviour and 
barriers such as forgetfulness, carelessness, adverse effects and efficacy. It includes four simple 
dichotomous questions, assigning one point for each yes response; total scores are categorised as: 0= 
high; 1-2= medium, and 3-4= low medication adherence behaviours (Morisky et al., 1986).  
The Adherence to Refills and Medications Scale (ARMS) (Kripalani, Risser, Gatti, & Jacobson, 
2009) will be used to determine medication adherence behaviour in terms of self-regulation. The ARMS 
is a 12-item scale: an eight-item medication-taking subscale assessing correct self-administration for 
the prescribed medications; and a four-item prescription refill subscale evaluating the patient’s ability 
to replenish medications on schedule. Each item is scored on a four-point scale ranging from l= none 
of the time to 4= all the time on a four-point Likert scale, with higher numbers demonstrating better 
refill ability for medications on schedule (Kripalani et al., 2009).  
The Belief about Medicine Questionnaire (BaMQ) (Horne, Weinman, & Hankins, 1999) elicits 
information on patients’ beliefs about medications which may be adherence-related. It identifies 
whether the patient believes in the necessity of their medicines or has concerns about them. The study 
will use the short (eight-item) version of the BaMQ developed by Horne et al. (1999), composed of four 
subscales of two items each, assessing: specific necessity, specific concerns, general overuse and 
general harm. Answers range from l= strongly disagree to 5= strongly agree on a five-point Likert scale; 
scores are summed to derive a total score, with higher scores indicating more positive beliefs.  
The Medication Adherence Self-Efficacy Scale-Revised (MASESE-R) (Fernandez, Chaplin, 
Schoenthaler, & Ogedegbe, 2008) consists of 13 items that evaluate an individual’s ability to adhere to 





taking medications in specific circumstances (e.g. with family, in public places, feeling well), and one 
assess the ability to take medications as part of the everyday routine. Each item is scored on a four-
point Likert scale, ranging from 0= not at all sure to 3= extremely sure. A single score is derived from 
the mean of all items, with greater self-efficacy indicated by high scores (Fernandez et al., 2008).  
The Medication Specific Social Support (MSSS) scale (Lehavot et al., 2011) is an eight-item 
survey of medication-specific social support to identify how often others help patients with their 
medication, scored for each item ranging from 0= never to 4= very often. A single mean score is 
presented as a medication-specific index of support (Lehavot et al., 2011). 
Validity and reliability 
The MAQ is a validated four-item tool suitable for  a wide range of conditions involving cardiac 
diseases (Nguyen, Caze, & Cottrell, 2014). Its validity and reliability has been determined in patients 
with hypertension, with a reported acceptable internal consistency of α = 0.61, sensitivity 0.81 and 
specificity 0.44 (Lavsa, Holzworth, & Ansani, 2011); it has also been validated in patients with heart 
failure, CVD and dyslipidemia (Afonso, Nassif, Aranha, DeLor, & Cardozo, 2006). MAQ score was 
found to be a significant independent predictor of cardiovascular nonadherence in a multivariate logistic 
regression model (Shalansky, Levy, & Ignaszewski, 2004) (Table 2). 
The ARMS subscales are highly correlated with the Morisky medication adherence four-item 
scale, and with medication refill adherence (Kripalani et al., 2009). The ARMS has been validated in 
patients with cardiovascular disease and other chronic diseases (Kripalani, Henderson, Jacobson, & 
Vaccarino, 2008). Among patients with low literacy skills (Kripalani et al., 2009) it has demonstrated 
high internal consistency using Cronbach’s α and test–retest reliability, set out in Table 2 (Kripalani et 
al., 2009).  
The BaMQ has been shown to correlate significantly with other adherence-related 
questionnaires such as MAQ, the Morisky medication adherence scale, and the medication adherence 
rating scale (MARS-5) (Gatti, Jacobson, Gazmararian, Schmotzer, & Kripalani, 2009; Horne et al., 
1999; Mårdby, Åkerlind, & Jörgensen, 2007). Each BMQ subscale has been evaluated for internal 





BaMQ categories correlated highly with patients’ beliefs about the adverse effects of medication and 
specific- concerns as assessed by the Sensitive-Soma Scale administered to general medical and cardiac 
groups (Table 2) (Horne et al., 1999).  
The MASES-R has been found to correlate significantly with electronic medication adherence 
records (MEMS) at three-months, confirming its predictive validity (Fernandez et al., 2008). The 
concurrent validity of the MASES-R has also been confirmed (Table 2). 
Data Analysis  
Phase one: Descriptive statistics will be used to analyse data related to the patients’ baseline 
characteristics. Data will be checked and cleaned prior to entry into SPSS for Windows version 23. 
Measures of central tendency and dispersion will describe the values of medication adherence, 
medication adherence self-efficacy, and beliefs about medication. Bivariate analyses will be conducted 
to examine factors potentially associated with medication non-adherence. Factors and behaviours 
related to medication non-adherence will be examined by logistic regression. Two sided testes will be 
conducted with significance set at .05. 
Phase two: Qualitative data will be analysed inductively using thematic analysis (Sim, 1998). This 
approach will focus on recognising, analysing and reporting recurrent patterns (themes) and 
subcategories within the data (Liamputtong, 2013). Simultaneous collection, transcription and analysis 
allows the researcher to build on emerging themes (Polit & Beck, 2014). Data will be examined and 
compared to identify similarities and differences by reading and searching within transcripts and across 
the data set (Polit & Beck, 2014). QSR NVivo software will be used to code and construct thematic 
analysis (Braun & Clarke, 2006). A similar but separate process will be employed with the data 
collected in response to the open questions at six months. 
Pilot RCT phase: Data will be analysed according to the intention to treat principles. Using survey and 
demographic data, the two groups will be compared at baseline and any differences taken into account 
during the outcome assessment. Paired samples t-test analysis will be used to test within-group 
differences on the medication adherence questionnaire scores (MSSS, MAQ, ARMS, BaMQ, and 





groups. Multinomial regression analysis will be applied to identify variables that significantly influence 
adherence to medication, such as self-efficacy, beliefs, level of confidence, or social support. Variables 
exerting significant influence on medication adherence in bivariate analysis will be entered in the 
regression analysis, with significance set at P<0.25 for the preliminary bivariate analysis and P <0.05 
for the regression analysis (Polit., 1996).  
Ethical considerations  
Approvals to conduct this study were granted by the appropriate health district and university Human 
Research Ethics Committees in June 2016 (reference numbers: 16/085 (HREC/16/POWH/218; ETH16-
0635). The study is registered as a clinical trial (ACTRN12616000910404) on www.anzctr.org.au. 
Discussion  
Patients with CVD often have multiple chronic illnesses requiring multiple prescriptions. Studies of 
long-term medication adherence outcomes are limited (Bansilal et al., 2016) although non-adherence is 
common in these patients and accounts for substantial morbidity and mortality (Albert, 2008). Adequate 
medication adherence may help improve quality of life by improving disease outcomes (Luszczynska 
et al., 2007). Better medication adherence may be achieved with interventions that address the known 
multiple factors of non-adherence, including lack of patient knowledge of perceived benefits, the 
perceived harm of medications, poor medication management and inadequate social support (Calvert et 
al., 2012).  
Medication adherence interventions for patients with CVD have been shown to be effective 
when delivered by nurses, who should play an active role in designing and applying such interventions 
(Albert, 2008; Chase et al., 2016). A recent systematic review emphasised that cardiac rehabilitation 
and prevention programs should encompass a dedicated strategy for medication adherence; at present, 
the majority of these programs do not measure and report adherence outcomes appropriately (Santo et 
al., 2016). There is scope for medication adherence interventions using techniques focused on 
promoting behavioural change to become part of routine health care (Easthall et al., 2013). This study 





adherence in a robust pilot trial using a RCT design, in line with the findings and recommendations of 
the recent review of medication adherence interventions for this population by Al Ganmi et al. (2016).   
Limitations 
This study has some potential limitations. Firstly, use of a multi-faceted intervention, while 
recommended as likely to increase the success of intervention as a whole, challenges researchers to 
identify the contribution of the individual components. This study attempts to address this by seeking 
participants’ experiences of each separate component of the intervention. Secondly, measuring 
medication adherence through self-reporting may introduce a response bias presenting potential 
problems with reliability. Also, social desirability bias is possible due to lack of blinding. Self-reporting 
is a commonly used method of outcome assessment for medication adherence as it is acceptable to 
participants and imposes a minimal burden. It also has the potential to explore medication adherence 
behaviour, adherence-related barriers and beliefs about medicines which may support beneficial 
medication adherence assessment in chronic disease management. Finally, participants are 
predominantly older adults who will be asked to spend 20 - 30 minutes answering 45 questions in Phase 
one (repeated at six months for participants in the intervention group) and 30-45 minutes in the Phase 
two interview. This may challenge their stamina, patience and tolerance.  
Conclusion 
Medication non-adherence among patients with CVD is a major problem. Multi-faceted medication 
adherence interventions comprising motivational interviews and text reminders may improve adherence 
to cardiac medication regimens by targeting individual behaviour change. This pilot study will provide 
important information about techniques appropriate for use by nurses to support medication compliance 
in their patients. Findings may support development of further trials of this intervention in out-patient 
cardiac care settings ahead of translation into routine clinical care. It may also be suitable for 
implementing in other health care areas and long-term patient groups.  
If this and further trials are successful, important next steps will be to consider the potential for 
widespread roll-out, including training nurses in motivational interviewing techniques. Software 





messages. The time requirement of the intervention will need to be considered for staffing rosters and 
patient appointments. A full cost-effectiveness analysis is therefore recommended.  
This protocol sets out the essential first steps for what may be an exciting new development in 
the contribution of nursing staff to delivering a substantial benefit to a sizeable patient group where 
there is clear potential for significant improvement in adherence.  
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